GlassScriptPhysician profile
Sabeena Arora
NPI 1316145840
$7,750.19
in general payments reported to CMS, 2019-2025
14 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $5,023 · 2021: $177 · 2022: $63.47 · 2023: $232 · 2024: $602 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $955 · Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $954.91 |
| Food and Beverage | $649.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $5,891.73 | 2019-2024 | Onpattro |
| Bridgebio Pharma, INC. | $643.88 | 2025 | Attruby |
| Pfizer INC. | $588.95 | 2019-2024 | |
| Abbott Laboratories | $151.65 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $132.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $101.58 | 2021-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $61.51 | 2023-2025 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $48.41 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $29.69 | 2022 | |
| Baxter Healthcare | $27.55 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $20.28 | 2023 | |
| Akcea Therapeutics, INC. | $20.01 | 2021 | |
| Merck Sharp & Dohme LLC | $16.59 | 2023 | Verquvo |
| Novo Nordisk INC | $16.01 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabeena Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.